{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:46:25Z","timestamp":1791773185424,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011933","name":"Chongqing Science and Technology Foundation","doi-asserted-by":"publisher","award":["CSTB2022NSCQ-MSX0805"],"award-info":[{"award-number":["CSTB2022NSCQ-MSX0805"]}],"id":[{"id":"10.13039\/501100011933","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>New\u00a0oral\u00a0anticoagulants\u00a0(NOACs) have been becoming prevalent in recent years and are\u00a0increasingly\u00a0used in the treatment of port vein thrombosis. The difference of the efficacy and safety between rivaroxaban and dabigatran remains unclear in the treatment of cirrhotic patients with acute portal vein thrombosis (PVT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study included all consecutive cirrhotic patients with acute portal vein thrombosis in our institute from January 2020 to December 2021. The patients received oral anticoagulation with rivaroxaban or dabigatran. The demographic, clinical, and imaging data of patients were collected. The diagnosis of acute PVT was confirmed by imaging examinations. The severity of liver cirrhosis was assessed using Child\u2013Pugh score and Model for End-Stage Liver Disease (MELD) score. Outcomes included recanalization (complete, partial, and persistent occlusion), liver function, bleedings, and survival. The log-rank test was used to compare Kaplan\u2013Meier distributions of time-to-event outcomes. The Cox proportional hazards model was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 94 patients were included, 52 patients (55%) received rivaroxaban and 42 (45%) with dabigatran. The complete and partial recanalization of PVT was observed in 41 patients. There was no significant difference in complete recanalization, partial recanalization, and persistent occlusion between the two groups. With multivariate analysis, D-dimer (HR 1.165, 95% CI 1.036\u20131.311, <jats:italic>p<\/jats:italic>\u2009=\u20090.011) was independent predictors of complete recanalization. The Child\u2013Pugh score (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) was significantly improved in both two groups after anticoagulation, respectively. However, there was no difference between the two groups. The probability of survival was 94%, 95% in the rivaroxaban and dabigatran groups (log-rank <jats:italic>p<\/jats:italic>\u2009=\u20090.830). Major bleedings were reported in 3 patients (6%) in rivaroxaban group and 1 patient (2%) in dabigatran group (<jats:italic>p<\/jats:italic>\u2009=\u20090.646). Six patients (12%) in rivaroxaban group experienced minor bleeding, and five (12%) from dabigatran group (<jats:italic>p<\/jats:italic>\u2009=\u20090.691).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The efficacy and safety were comparable between rivaroxaban and dabigatran in the treatment of cirrhotic patients with acute portal vein thrombosis. And D-dimer can contribute to the prediction of PVT recanalization in cirrhotic patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-02960-8","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T13:02:38Z","timestamp":1695646958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis"],"prefix":"10.1186","volume":"23","author":[{"given":"Haonan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingdong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixiong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"issue":"11","key":"2960_CR1","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/jcm10112316","volume":"10","author":"C Zhan","year":"2021","unstructured":"Zhan C, Prabhu V, Kang SK, Li C, Zhu Y, Kim S, Olsen S, Jacobson IM, Dagher NN, Carney B, et al. Comparison of non-tumoral portal vein thrombosis management in cirrhotic patients: TIPS versus anticoagulation versus no treatment. J Clin Med. 2021;10(11):2316.","journal-title":"J Clin Med"},{"issue":"2","key":"2960_CR2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41395-018-0421-0","volume":"114","author":"I Pettinari","year":"2019","unstructured":"Pettinari I, Vukotic R, Stefanescu H, Pecorelli A, Morelli M, Grigoras C, Sparchez Z, Andreone P, Piscaglia F, Bo L. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis. Am J Gastroenterol. 2019;114(2):258\u201366.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2960_CR3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.27546","volume":"61","author":"F Nery","year":"2015","unstructured":"Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, Plessier A, Roulot D, Chaffaut C, Bourcier V, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015;61(2):660\u20137.","journal-title":"Hepatology"},{"issue":"1","key":"2960_CR4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1148\/radiol.2021203051","volume":"299","author":"S Nardelli","year":"2021","unstructured":"Nardelli S, Riggio O, Turco L, Gioia S, Puzzono M, Bianchini M, Ridola L, Aprile F, Gitto S, Pelle G, et al. Relevance of spontaneous portosystemic shunts detected with ct in patients with cirrhosis. Radiology. 2021;299(1):133\u201340.","journal-title":"Radiology"},{"issue":"1","key":"2960_CR5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3350\/cmh.2016.0110","volume":"23","author":"F Leonardi","year":"2017","unstructured":"Leonardi F, Maria N, Villa E. Anticoagulation in cirrhosis: a new paradigm? Clin Mol Hepatol. 2017;23(1):13\u201321.","journal-title":"Clin Mol Hepatol"},{"issue":"13\u201314","key":"2960_CR6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00508-018-1351-y","volume":"130","author":"B Scheiner","year":"2018","unstructured":"Scheiner B, Stammet PR, Pokorny S, Bucsics T, Schwabl P, Brichta A, Thaler J, Lampichler K, Ba-Ssalamah A, Ay C, et al. Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. Wien Klin Wochenschr. 2018;130(13\u201314):446\u201355.","journal-title":"Wien Klin Wochenschr"},{"issue":"4","key":"2960_CR7","first-page":"432","volume":"8","author":"M Rugivarodom","year":"2020","unstructured":"Rugivarodom M, Charatcharoenwitthaya P. Nontumoral portal vein thrombosis: a challenging consequence of liver cirrhosis. J Clin Transl Hepatol. 2020;8(4):432\u201344.","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"2960_CR8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.14218\/JCTH.2015.00014","volume":"3","author":"TP Sabol","year":"2015","unstructured":"Sabol TP, Molina M, Wu GY. Thrombotic venous diseases of the liver. J Clin Transl Hepatol. 2015;3(3):189\u201394.","journal-title":"J Clin Transl Hepatol"},{"issue":"7","key":"2960_CR9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","volume":"10","author":"MG Delgado","year":"2012","unstructured":"Delgado MG, Seijo S, Yepes I, Ach\u00e9car L, Catalina MV, Garc\u00eda-Criado A, Abraldes JG, de la Pe\u00f1a J, Ba\u00f1ares R, Albillos A, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012;10(7):776\u201383.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2960_CR10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","volume":"64","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver. Electronic address eee: EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64(1):179\u2013202.","journal-title":"J Hepatol"},{"issue":"1","key":"2960_CR11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","volume":"73","author":"PG Northup","year":"2021","unstructured":"Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases. Hepatology (Baltimore, MD). 2021;73(1):366\u2013413.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"4","key":"2960_CR12","doi-asserted-by":"crossref","first-page":"e12512","DOI":"10.1002\/rth2.12512","volume":"5","author":"J Beyer-Westendorf","year":"2021","unstructured":"Beyer-Westendorf J, Marten S. Reproductive issues in women on direct oral anticoagulants. Res Pract Thromb Haemost. 2021;5(4):e12512.","journal-title":"Res Pract Thromb Haemost"},{"key":"2960_CR13","doi-asserted-by":"crossref","first-page":"e066785","DOI":"10.1136\/bmj-2021-066785","volume":"376","author":"M Marcucci","year":"2022","unstructured":"Marcucci M, Etxeandia-Ikobaltzeta I, Yang S, Germini F, Gupta S, Agarwal A, Ventresca M, Tang S, Morgano GP, Wang M, et al. Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials. BMJ. 2022;376:e066785.","journal-title":"BMJ"},{"issue":"23","key":"2960_CR14","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","volume":"3","author":"DR Anderson","year":"2019","unstructured":"Anderson DR, Morgano GP, Bennett C, Dentali F, Francis CW, Garcia DA, Kahn SR, Rahman M, Rajasekhar A, Rogers FB, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019;3(23):3898\u2013944.","journal-title":"Blood Adv"},{"issue":"1","key":"2960_CR15","first-page":"49","volume":"18","author":"D Imberti","year":"2020","unstructured":"Imberti D, Pomero F, Mastroiacovo D. Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study. Blood Transfus. 2020;18(1):49\u201357.","journal-title":"Blood Transfus"},{"issue":"6","key":"2960_CR16","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cpt.2369","volume":"110","author":"N Gronich","year":"2021","unstructured":"Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther. 2021;110(6):1526\u201336.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2960_CR17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s12325-017-0488-9","volume":"34","author":"R De Caterina","year":"2017","unstructured":"De Caterina R, Ageno W, Boriani G, Colonna P, Ghirarduzzi A, Patti G, Rossini R, Rubboli A, Schinco P, Agnelli G. Edoxaban in atrial fibrillation and venous thromboembolism-ten key questions and answers: a practical guide. Adv Ther. 2017;34(3):620\u201337.","journal-title":"Adv Ther"},{"issue":"9","key":"2960_CR18","doi-asserted-by":"crossref","first-page":"e031341","DOI":"10.1136\/bmjopen-2019-031341","volume":"9","author":"LA Garcia Rodriguez","year":"2019","unstructured":"Garcia Rodriguez LA, Martin-Perez M, Vora P, Roberts L, Balabanova Y, Brobert G, Fatoba S, Suzart-Woischnik K, Schaefer B, Ruigomez A. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. BMJ Open. 2019;9(9):e031341.","journal-title":"BMJ Open"},{"issue":"9","key":"2960_CR19","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.3390\/ijerph18094443","volume":"18","author":"P Manckoundia","year":"2021","unstructured":"Manckoundia P, Nuemi G, Hacquin A, Menu D, Rosay C, Vovelle J, Nuss V, Baudin-Senegas C, Barben J, Putot A. Direct oral anticoagulants versus vitamin K antagonists in patients aged 80 years and older. Int J Environ Res Public Health. 2021;18(9):4443.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"2960_CR20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12872-020-01340-4","volume":"20","author":"A Briasoulis","year":"2020","unstructured":"Briasoulis A, Gao Y, Inampudi C, Alvarez P, Asleh R, Chrischilles E, Leira EC, Vaughan-Sarrazin M. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses. BMC Cardiovasc Disord. 2020;20(1):42.","journal-title":"BMC Cardiovasc Disord"},{"issue":"10","key":"2960_CR21","doi-asserted-by":"crossref","first-page":"e00409","DOI":"10.14309\/ctg.0000000000000409","volume":"12","author":"S Xu","year":"2021","unstructured":"Xu S, Guo X, Yang B, Romeiro FG, Primignani M, M\u00e9ndez-S\u00e1nchez N, Yoshida EM, Mancuso A, Tacke F, Noronha Ferreira C, et al. Evolution of nonmalignant portal vein thrombosis in liver cirrhosis: a pictorial review. Clin Transl Gastroenterol. 2021;12(10):e00409.","journal-title":"Clin Transl Gastroenterol"},{"key":"2960_CR22","doi-asserted-by":"crossref","first-page":"920361","DOI":"10.1155\/2015\/920361","volume":"2015","author":"A Zalpour","year":"2015","unstructured":"Zalpour A, Oo TH. Update on edoxaban for the prevention and treatment of thromboembolism: clinical applications based on current evidence. Adv Hematol. 2015;2015:920361.","journal-title":"Adv Hematol"},{"issue":"1","key":"2960_CR23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/jpm9010007","volume":"9","author":"SH Kanuri","year":"2019","unstructured":"Kanuri SH, Kreutz RP. Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019;9(1):7.","journal-title":"J Pers Med"},{"issue":"12","key":"2960_CR24","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.amjcard.2007.07.036","volume":"100","author":"RW Yeh","year":"2007","unstructured":"Yeh RW, Wiviott SD, Giugliano RP, Morrow DA, Shui A, Qin J, Scirica B, Bradner JE, Jang I-K, Gibson CM, et al. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. Am J Cardiol. 2007;100(12):1734\u20138.","journal-title":"Am J Cardiol"},{"issue":"7","key":"2960_CR25","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/hep4.1914","volume":"6","author":"A Talwar","year":"2022","unstructured":"Talwar A, Varghese J, Knight GM, Katariya N, Caicedo J-C, Dietch Z, Borja-Cacho D, Ladner D, Christopher D, Baker T, et al. Preoperative portal vein recanalization-transjugular intrahepatic portosystemic shunt for chronic obliterative portal vein thrombosis: outcomes following liver transplantation. Hepatol Commun. 2022;6(7):1803\u201312.","journal-title":"Hepatol Commun"},{"issue":"4","key":"2960_CR26","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959\u201374.","journal-title":"J Hepatol"},{"issue":"9","key":"2960_CR27","doi-asserted-by":"crossref","first-page":"e00228","DOI":"10.14309\/ctg.0000000000000228","volume":"11","author":"T Zhou","year":"2020","unstructured":"Zhou T, Sun X, Zhou T, Li Y, Chen X, Cheng B, Gao Y. Efficacy and safety of nadroparin calcium-warfarin sequential anticoagulation in portal vein thrombosis in cirrhotic patients: a randomized controlled trial. Clin Transl Gastroenterol. 2020;11(9):e00228.","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"2960_CR28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12959-022-00379-x","volume":"20","author":"K Al Sulaiman","year":"2022","unstructured":"Al Sulaiman K, Badreldin HA, Korayem GB, Alenazi AA, Alsuwayyid F, Alrashidi A, Alhijris M, Almutairi F, Alharthi F, Vishwakarma R, et al. Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study. Thromb J. 2022;20(1):25.","journal-title":"Thromb J"},{"issue":"9921","key":"2960_CR29","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362.","journal-title":"Lancet"},{"issue":"3","key":"2960_CR30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","volume":"12","author":"T van der Hulle","year":"2014","unstructured":"van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320\u20138.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2960_CR31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/jth.13566","volume":"15","author":"A Kapoor","year":"2017","unstructured":"Kapoor A, Ellis A, Shaffer N, Gurwitz J, Chandramohan A, Saulino J, Ishak A, Okubanjo T, Michota F, Hylek E, et al. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. J Thromb Haemost. 2017;15(2):284\u201394.","journal-title":"J Thromb Haemost"},{"issue":"13","key":"2960_CR32","doi-asserted-by":"crossref","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E. A Warden B: direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"2960_CR33","doi-asserted-by":"crossref","first-page":"e003343","DOI":"10.1136\/bmjopen-2013-003343","volume":"3","author":"PK Maccallum","year":"2013","unstructured":"Maccallum PK, Mathur R, Hull SA, Saja K, Green L, Morris JK, Ashman N. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open. 2013;3(9):e003343.","journal-title":"BMJ Open"},{"issue":"9","key":"2960_CR34","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2013.11.013","volume":"63","author":"SG Goodman","year":"2014","unstructured":"Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;63(9):891\u2013900.","journal-title":"J Am Coll Cardiol"},{"issue":"10264","key":"2960_CR35","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","volume":"396","author":"N Chan","year":"2020","unstructured":"Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet. 2020;396(10264):1767\u201376.","journal-title":"Lancet"},{"issue":"7","key":"2960_CR36","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/jth.12591","volume":"12","author":"E Perzborn","year":"2014","unstructured":"Perzborn E, Heitmeier S, Buetehorn U, Laux V. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. J Thromb Haemost. 2014;12(7):1054\u201365.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2960_CR37","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.27350","volume":"61","author":"W Potze","year":"2015","unstructured":"Potze W, Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. Hepatology (Baltimore, MD). 2015;61(4):1435\u20136.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"2960_CR38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-015-2566-x","volume":"95","author":"JK Schaefer","year":"2016","unstructured":"Schaefer JK, McBane RD, Wysokinski WE. How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Ann Hematol. 2016;95(3):437\u201349.","journal-title":"Ann Hematol"},{"issue":"1","key":"2960_CR39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ane.13506","volume":"145","author":"G Nepal","year":"2022","unstructured":"Nepal G, Kharel S, Bhagat R, Ka Shing Y, Ariel Coghlan M, Poudyal P, Ojha R, Sunder Shrestha G. Safety and efficacy of direct oral anticoagulants in cerebral venous thrombosis: a meta-analysis. Acta Neurol Scand. 2022;145(1):10\u201323.","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"2960_CR40","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41390-022-02294-3","volume":"93","author":"J Chen","year":"2023","unstructured":"Chen J, Bi G, Wu F, Qin X. Direct oral anticoagulants versus standard anticoagulation in children treated for acute venous thromboembolism. Pediatr Res. 2023;93(6):1491\u20138.","journal-title":"Pediatr Res."},{"key":"2960_CR41","first-page":"8859602","volume":"2021","author":"H Chen","year":"2021","unstructured":"Chen H, Lei J, Liang S, Luo G, Deng M, Lu M. Safety and efficacy of anticoagulation in patients with cirrhosis: a meta-analysis. Can J Gastroenterol Hepatol. 2021;2021:8859602.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"2","key":"2960_CR42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11739-023-03206-x","volume":"18","author":"Z Gao","year":"2023","unstructured":"Gao Z, Li S, Zhao J, Li J, Gao Y. Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial. Intern Emerg Med. 2023;18(2):513\u201321.","journal-title":"Intern Emerg Med"},{"issue":"5","key":"2960_CR43","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","volume":"143","author":"E Villa","year":"2012","unstructured":"Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253-1260 e1254.","journal-title":"Gastroenterology"},{"issue":"2","key":"2960_CR44","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","volume":"153","author":"L Loffredo","year":"2017","unstructured":"Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology. 2017;153(2):480-487.e1.","journal-title":"Gastroenterology"},{"issue":"1","key":"2960_CR45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12872-022-02550-8","volume":"22","author":"Z-Y Liu","year":"2022","unstructured":"Liu Z-Y, Zhang H-X, Ma L-Y, Mu G-Y, Xie Q-F, Zhou S, Wang Z-N, Wang Z, Hu K, Xiang Q, et al. Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies. BMC Cardiovasc Disord. 2022;22(1):105.","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"2960_CR46","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.cgh.2013.09.010","volume":"12","author":"A Ootani","year":"2014","unstructured":"Ootani A, Hayashi Y, Miyagi Y. Dabigatran-induced esophagitis. Clin Gastroenterol Hepatol. 2014;12(7):e55\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2960_CR47","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3949\/ccjm.86a.18117","volume":"86","author":"Y Kajihara","year":"2019","unstructured":"Kajihara Y. Dabigatran-induced esophagitis. Cleve Clin J Med. 2019;86(5):303\u20134.","journal-title":"Cleve Clin J Med"},{"issue":"17","key":"2960_CR48","doi-asserted-by":"crossref","first-page":"e19890","DOI":"10.1097\/MD.0000000000019890","volume":"99","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Dai Y, Lu L, Fu Z. Dabigatran-induced esophagitis: a case report. Medicine (Baltimore). 2020;99(17):e19890.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2960_CR49","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/jgh.13024","volume":"31","author":"Y Toya","year":"2016","unstructured":"Toya Y, Nakamura S, Tomita K, Matsuda N, Abe K, Abiko Y, Orikasa S, Akasaka R, Chiba T, Uesugi N, et al. Dabigatran-induced esophagitis: the prevalence and endoscopic characteristics. J Gastroenterol Hepatol. 2016;31(3):610\u20134.","journal-title":"J Gastroenterol Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02960-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-02960-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02960-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:07:19Z","timestamp":1700611639000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-02960-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2960"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-02960-8","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"assertion":[{"value":"16 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved and waived informed consent by Ethics Committee of the Second Hospital of Chongqing Medical University. The study was performed in accordance with relevant guidelines and regulations and no experiments were performed on humans and\/or human tissue samples. The ethics committee review boards waived the need for informed consent. (Related files).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"329"}}